NYSE · Pharmaceutical Preparations
JOHNSON & JOHNSONJNJ
JOHNSON & JOHNSON (JNJ) is listed on NYSE; the SEC classifies it under "Pharmaceutical Preparations". For fiscal 2025 (ended Dec 28, 2025) it reported revenue of $94.19B, up 6.0% from fiscal 2024. Net income was $26.8B, a net margin of 28.5%.
Company profile
- Ticker
- JNJ
- Exchange
- NYSE
- Industry (SIC)
- Pharmaceutical PreparationsSIC 2834
- Fiscal year end
- January 3
- Headquarters
- New Brunswick, NJ
- Incorporated in
- NJ
- SEC filer category
- Large accelerated filer
- SEC CIK
- 200406
Key financials (annual, 10-K)
| Key financials (annual, 10-K) | FY2025ended Dec 28, 2025 | FY2024ended Dec 29, 2024 | FY2023ended Dec 31, 2023 | FY2022ended Jan 1, 2023 | FY2021ended Jan 2, 2022 |
|---|---|---|---|---|---|
| Revenue | $94.19B | $88.82B | $85.16B | $94.94B | $93.78B |
| Revenue growth (YoY) | +6.05% | +4.30% | -10.31% | +1.25% | — |
| Net income | $26.8B | $14.07B | $35.15B | $17.94B | $20.88B |
| Net income growth (YoY) | +90.56% | -59.99% | +95.94% | -14.07% | — |
| Net margin | 28.5% | 15.8% | 41.3% | 18.9% | 22.3% |
| Diluted EPS | $11.03 | $5.79 | $13.72 | $6.73 | $7.81 |
| Total assets | $199.21B | $180.1B | $167.56B | $187.38B | $182.02B |
| Total liabilities | $117.67B | $108.61B | $98.78B | $110.57B | $108B |
| Stockholders' equity | — | — | — | — | — |
| Equity ratio (equity / assets) | — | — | — | — | — |
| Cash and cash equivalents | $19.71B | $24.11B | $21.86B | $14.13B | $14.49B |
| Shares outstanding | 2.41B | 2.41B | 2.41B | 2.6B | 2.63B |
Values as reported in each fiscal year's Form 10-K (XBRL data on SEC EDGAR); growth and ratios are computed from those values. Revenue is the total revenue figure the company tagged (omitted when the only figure tagged is evidently partial, e.g. below net income); growth is only shown between consecutive ~12-month fiscal years reported with the same revenue measure. Per-share figures and share counts are as reported and not adjusted for later stock splits. — = not reported.
Recent SEC filings
All filings on SEC EDGAR- 10-QQuarterly reportPeriod: Sep 27, 2026Filed: Oct 21, 2026
- 8-KCurrent reportFiled: Oct 13, 2026
- 8-KCurrent reportFiled: Aug 4, 2026
- 8-KCurrent reportFiled: Jul 29, 2026
- 8-KCurrent reportPeriod: Jul 27, 2026Filed: Jul 28, 2026
- 10-QQuarterly reportPeriod: Jun 28, 2026Filed: Jul 23, 2026
- 8-KCurrent reportFiled: Jul 15, 2026
- 8-KCurrent reportPeriod: Apr 23, 2026Filed: Apr 28, 2026
- 10-QQuarterly reportPeriod: Mar 29, 2026Filed: Apr 22, 2026
- 8-KCurrent reportFiled: Apr 14, 2026
Frequently asked questions
What does JOHNSON & JOHNSON do?
The SEC classifies JOHNSON & JOHNSON under Standard Industrial Classification (SIC) code 2834, "Pharmaceutical Preparations". It is headquartered in New Brunswick, NJ. It is incorporated in NJ. In fiscal 2025 it reported revenue of $94.19B and net income of $26.8B in its annual 10-K report.
What was JOHNSON & JOHNSON's revenue in 2025?
JOHNSON & JOHNSON reported revenue of $94.19B for fiscal 2025, which ended Dec 28, 2025, up 6.0% from $88.82B in fiscal 2024, according to its annual 10-K report filed with the SEC on Feb 11, 2026.
What was JOHNSON & JOHNSON's net income in 2025?
JOHNSON & JOHNSON reported net income of $26.8B for fiscal 2025, a net margin of 28.5% of revenue.
Where is JOHNSON & JOHNSON listed?
According to the SEC, JOHNSON & JOHNSON's ticker JNJ is listed on NYSE.
When does JOHNSON & JOHNSON's fiscal year end?
According to the SEC, JOHNSON & JOHNSON's fiscal year ends on January 3; its latest reported fiscal year (2025) ended Dec 28, 2025.
Companies in the same industry
All US stocksSource: SEC EDGAR · Last updated:
Ver en españolNot investment advice: This page shows financial data that companies reported to the US Securities and Exchange Commission, for information only. It is not investment advice or a recommendation to buy or sell any security, and it shows no stock prices. Data may be incomplete, restated or out of date — check the original filings on SEC EDGAR before making decisions.